Abstract
Diabetes mellitus (DM) is a serious and common chronic disease with high morbidity and mortality rates. Recently, stem cell-based therapy has shown considerable promise as a future therapeutic modality for DM. This review aims to summarize the types of stem cells that have the most successful evidence in treating type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM), and also to assess the safety and efficacy of different types of stem cells in the treatment of DM. PubMed, MEDLINE, and PubMed Central databases were searched up to October 15, 2020, using medical subject heading (MeSH) terms. After application of inclusion criteria and exclusion criteria, 10 studies were included in our final review: six T1DM studies including 120 patients, and four T2DM studies including 65 patients. Our data showed that autologous and allogeneic stem cell therapy is a relatively safe and effective method for selected individuals with DM. The best therapeutic outcome was achieved by transplantation of bone marrow hemopoietic stem cells (BM-HSCs) for T1DM and bone marrow mononuclear cells (BM-MNCs) along with mesenchymal stromal cells (MSCs) for T2DM. However, patients with DKA are not a good candidate for stem cell transplantation. Further rigorous experiments are needed in order to be able to establish stem cell-based therapies as the future standard of care for treating DM.
Highlights
BackgroundDiabetes mellitus (DM) is one of the fastest-growing international health problems of the 21st century [1]
This review aims to summarize the types of stem cells that have the most successful evidence in treating type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM), and to assess the safety and efficacy of different types of stem cells in the treatment of DM
The best therapeutic outcome was achieved by transplantation of bone marrow hemopoietic stem cells (BM-hematopoietic stem cells (HSCs)) for T1DM and bone marrow mononuclear cells (BM-MNCs) along with mesenchymal stromal cells (MSCs) for T2DM
Summary
BackgroundDiabetes mellitus (DM) is one of the fastest-growing international health problems of the 21st century [1]. According to a report from the International Diabetes Federation, there were 463 million diabetic patients worldwide in 2019 This number is expected to grow to 538 million by 2030 [1]. T1DM is caused by autoimmune destruction of insulin-producing beta-cells of the pancreas, resulting in partial or complete insulin deficiency. The cause of this reaction is not fully understood; it is believed to be due to a combination of genetic predispositions and environmental triggers that initiate the destructive autoimmune process [2,3]. The Collaborative Islet Transplant Registry (CITR) demonstrates that 44% of recipients were insulin-independent for three years post-transplantation, and the development of DM complications has been successfully postponed. Anti-CD3 monoclonal antibody therapy, considered moderately safe, obtained insulin independence in only 5% of participants after two years of follow-up [8]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
